Cancer Med. 2017 Apr 3. doi: 10.1002/cam4.1037. [Epub ahead of print]
StrandAdvantage test for early-line and advanced-stage treatment decisions in solid tumors.
Sen M1,2, Katragadda S1, Ravichandran A1, Deshpande G1, Parulekar M1, Nayanala S1, Vittal V1, Shen W3, Phooi Nee Yong M3, Jacob J1, Parchuru S1,2, Dhanuskodi K1,2, Eyring K3, Agrawal P1, Agarwal S1, Shanmugam A1, Gupta S1, Vishwanath D1,2, Kumari K1,2, Hariharan AK1,2, Balaji SA1,2, Liang Q3, Robolledo B3, Gauribidanur Raghavendrachar V1, Oomer Farooque M1, Buresh CJ4, Ramamoorthy P3, Bahadur U1, Subramanian K1, Hariharan R1, Veeramachaneni V1, Sankaran S1, Gupta V1,2.
© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Clinical utility; immunohistochemistry; next-generation sequencing; solid tumors; standard-of-care therapy
Free full text